{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:55:45Z","timestamp":1789070145846,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Dr. Falk Pharma Benelux B.V.","award":["FALK-BNL-2016-029"],"award-info":[{"award-number":["FALK-BNL-2016-029"]}]},{"name":"Amsterdam UMC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s10620-020-06647-y","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T02:02:27Z","timestamp":1602813747000},"page":"2916-2924","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Impaired Quality of Working Life in Inflammatory Bowel Disease Patients"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9843-0134","authenticated-orcid":false,"given":"Sara","family":"van Gennep","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanne K. H.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke E.","family":"Gielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svend T.","family":"Rietdijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina B.","family":"Gecse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyriel Y.","family":"Ponsioen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolijn","family":"Duijvestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert R.","family":"D\u2019Haens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"L\u00f6wenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela G. E. M.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"key":"6647_CR1","doi-asserted-by":"publisher","first-page":"8182","DOI":"10.3748\/wjg.v23.i46.8182","volume":"23","author":"LM Spekhorst","year":"2017","unstructured":"Spekhorst LM, Oldenburg B, van Bodegraven AA, et al. Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease. World J Gastroenterol. 2017;23:8182\u20138192.","journal-title":"World J Gastroenterol"},{"key":"6647_CR2","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.crohns.2014.06.006","volume":"8","author":"K B\u00fcsch","year":"2014","unstructured":"B\u00fcsch K, da Silva SA, Holton M, Rabacow FM, Khalili H, Ludvigsson JF. Sick leave and disability pension in inflammatory bowel disease: a systematic review. J Crohns Colitis. 2014;8:1362\u20131377.","journal-title":"J Crohns Colitis"},{"key":"6647_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/ecco-jcc\/jjw145","volume":"11","author":"N Williet","year":"2017","unstructured":"Williet N, Sarter H, Gower-Rousseau C, et al. Patient-reported outcomes in a French nationwide survey of inflammatory bowel disease patients. J Crohns Colitis. 2017;11:165\u2013174.","journal-title":"J Crohns Colitis"},{"key":"6647_CR4","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1097\/MIB.0000000000000399","volume":"21","author":"A Zand","year":"2015","unstructured":"Zand A, van Deen WK, Inserra EK, et al. Presenteeism in inflammatory bowel diseases: a hidden problem with significant economic impact. Inflamm Bowel Dis. 2015;21:1623\u20131630.","journal-title":"Inflamm Bowel Dis"},{"key":"6647_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa082","author":"S van Gennep","year":"2020","unstructured":"van Gennep S, Evers SW, Rietdijk ST, et al. High disease burden drives indirect costs in employed inflammatory bowel disease patients: the WORK-IBD study. Inflamm Bowel Dis. 2020;. https:\/\/doi.org\/10.1093\/ibd\/izaa082.","journal-title":"Inflamm Bowel Dis"},{"key":"6647_CR6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000495293","volume":"3","author":"E Paulides","year":"2019","unstructured":"Paulides E, Gearry RB, de Boer NKH, Mulder CJJ, Bernstein CN, McCombie AM. Accommodations and adaptations to overcome workplace disability in inflammatory bowel disease patients: a systematic review. Inflamm Intest Dis. 2019;3:138\u2013144.","journal-title":"Inflamm Intest Dis"},{"key":"6647_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.15171\/ijhpm.2013.07","volume":"1","author":"AM Mosadeghrad","year":"2013","unstructured":"Mosadeghrad AM. Quality of working life: an antecedent to employee turnover intention. Int J Heal Policy Manag. 2013;1:43\u201350.","journal-title":"Int J Heal Policy Manag"},{"key":"6647_CR8","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1097\/JOM.0000000000000831","volume":"58","author":"AE Arnold","year":"2016","unstructured":"Arnold AE, Coffeng JK, Boot CRL, et al. The relationship between job satisfaction and productivity-related costs: a longitudinal analysis. J Occup Environ Med. 2016;58:874\u2013879.","journal-title":"J Occup Environ Med"},{"key":"6647_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.crohns.2012.12.014","volume":"8","author":"M D\u00fcr","year":"2014","unstructured":"D\u00fcr M, Sadlo\u0148ov\u00e1 M, Haider S, et al. Health determining concepts important to people with Crohn\u2019s disease and their coverage by patient-reported outcomes of health and wellbeing. J Crohn\u2019s Colitis. 2014;8:45\u201355.","journal-title":"J Crohn\u2019s Colitis"},{"key":"6647_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12885-017-3966-1","volume":"18","author":"M de Jong","year":"2018","unstructured":"de Jong M, Tamminga SJ, van Es RJJ, Frings-Dresen MHW, de Boer AGEM. The quality of working life questionnaire for cancer survivors (QWLQ-CS): factorial structure, internal consistency, construct validity and reproducibility. BMC Cancer. 2018;18:66.","journal-title":"BMC Cancer"},{"key":"6647_CR11","volume-title":"Castor electronic data capture","author":"BV Ciwit","year":"2018","unstructured":"Ciwit BV. Castor electronic data capture. Amsterdam: Ciwit B.V; 2018."},{"key":"6647_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353\u2013365.","journal-title":"Pharmacoeconomics"},{"key":"6647_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0022-3999(94)00125-O","volume":"39","author":"EM Smets","year":"1995","unstructured":"Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39:315\u2013325.","journal-title":"J Psychosom Res"},{"key":"6647_CR14","first-page":"1571","volume":"91","author":"EJ Irvine","year":"1996","unstructured":"Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn\u2019s Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571\u20131578.","journal-title":"Am J Gastroenterol"},{"key":"6647_CR15","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.crohns.2012.11.007","volume":"7","author":"F Bennebroek Evertsz\u2019","year":"2013","unstructured":"Bennebroek Evertsz\u2019 F, Nieuwkerk PT, Stokkers PCF, et al. The patient simple clinical colitis activity index (P-SCCAI) can detect ulcerative colitis (UC) disease activity in remission: a comparison of the P-SCCAI with clinician-based SCCAI and biological markers. J Crohns Colitis. 2013;7:890\u2013900.","journal-title":"J Crohns Colitis"},{"key":"6647_CR16","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1097\/MCG.0b013e31828b2196","volume":"47","author":"F Bennebroek Evertsz\u2019","year":"2013","unstructured":"Bennebroek Evertsz\u2019 F, Hoeks CCMQ, Nieuwkerk PT, et al. Development of the patient Harvey Bradshaw index and a comparison with a clinician-based Harvey Bradshaw index assessment of Crohn\u2019s disease activity. J Clin Gastroenterol. 2013;47:850\u2013856.","journal-title":"J Clin Gastroenterol"},{"key":"6647_CR17","doi-asserted-by":"publisher","first-page":"e12910","DOI":"10.1111\/ecc.12910","volume":"27","author":"SJ Tamminga","year":"2018","unstructured":"Tamminga SJ, de Jong M, Frings-Dresen MHW, de Boer AGEM. The Quality of Working Life Questionnaire for Cancer Survivors: sufficient responsiveness for use as a patient-reported outcome measurement. Eur J Cancer Care (Engl). 2018;27:e12910.","journal-title":"Eur J Cancer Care (Engl)"},{"key":"6647_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-2648.2007.04409.x","volume":"60","author":"D Van Laar","year":"2007","unstructured":"Van Laar D, Edwards JA, Easton S. The work-related quality of life scale for healthcare workers. J Adv Nurs. 2007;60:325\u2013333.","journal-title":"J Adv Nurs"},{"key":"6647_CR19","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s11764-015-0485-4","volume":"10","author":"M de Jong","year":"2016","unstructured":"de Jong M, Tamminga SJ, de Boer AGEM, Frings-Dresen MHW. Quality of working life of cancer survivors: development of a cancer-specific questionnaire. J Cancer Surviv. 2016;10:394\u2013405.","journal-title":"J Cancer Surviv"},{"key":"6647_CR20","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/MEG.0000000000000685","volume":"28","author":"AGEM De Boer","year":"2016","unstructured":"De Boer AGEM, Bennebroek Evertsz\u2019 F, Stokkers PC, et al. Employment status, difficulties at work and quality of life in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol. 2016;28:1130\u20131136.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"6647_CR21","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s00520-016-3549-8","volume":"25","author":"M de Jong","year":"2017","unstructured":"de Jong M, Tamminga SJ, Frings-Dresen MHW, de Boer AGEM. Quality of Working Life of cancer survivors: associations with health- and work-related variables. Support Care Cancer. 2017;25:1475\u20131484.","journal-title":"Support Care Cancer"},{"key":"6647_CR22","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.dld.2019.01.024","volume":"51","author":"C Le Berre","year":"2019","unstructured":"Le Berre C, Peyrin-Biroulet L, Buisson A, et al. Impact of inflammatory bowel diseases on working life: a French nationwide survey. Dig Liver Dis. 2019;51:961\u2013966.","journal-title":"Dig Liver Dis"},{"key":"6647_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41575-018-0091-9","volume":"16","author":"NZ Borren","year":"2019","unstructured":"Borren NZ, van der Woude CJ, Ananthakrishnan AN. Fatigue in IBD: epidemiology, pathophysiology and management. Nat Rev Gastroenterol Hepatol. 2019;16:247\u2013259.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"6647_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa057","author":"EM van Andel","year":"2020","unstructured":"van Andel EM, Koopmann BDM, Crouwel F, et al. Systematic review of development and content validity of patient-reported outcome measures in Inflammatory Bowel Disease: do we measure what we measure? J Crohns Colitis. 2020;. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa057.","journal-title":"J Crohns Colitis"},{"key":"6647_CR25","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.cgh.2008.06.010","volume":"6","author":"J Jones","year":"2008","unstructured":"Jones J, Loftus EV, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2008;6:1218\u20131224.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6647_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1136\/gut.35.2.231","volume":"35","author":"C Cellier","year":"1994","unstructured":"Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn\u2019s disease. A prospective multicentre study of 121 cases. The Groupe d\u2019Etudes Th\u00e9rapeutiques des Affections Inflammatoires Digestives. Gut. 1994;35:231\u2013235.","journal-title":"Gut"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06647-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-020-06647-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06647-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T12:28:01Z","timestamp":1634387281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-020-06647-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["6647"],"URL":"https:\/\/doi.org\/10.1007\/s10620-020-06647-y","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,16]]},"assertion":[{"value":"17 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"SG: none; NB: has served as a speaker for AbbVie, Takeda, and MSD. He has served as consultant and principal investigator for Takeda and TEVA Pharma B.V. He has received a (unrestricted) research grant from Dr. Falk, TEVA Pharma B.V, MLDS, and Takeda; MG: none; SR: none; KG: has received consultancy fees and\/or speaker\u2019s honoraria from AbbVie, Celltrion, Ferring, Immunic Therapeutics, Janssen, Pfizer, Roche, Sandoz, Samsung Bioepis, Takeda, and Tillotts; CP: has served as a speaker for Takeda, Tillotts, and Roche. He has served as advisor for Takeda, Pliant, and Shire. He has received grant support from Takeda. MD: reports advisory fees from Echo Pharma and Robarts Clinical Trials, Inc., speaker fees from Janssen, Merck & Co., Inc., Pfizer, Takeda and Tillotts Pharma, and nonfinancial support from Dr. Falk. GD: has served as advisor for Abbvie, Ablynx, Amakem, AM Pharma, Avaxia, Biogen, Bristol Meiers Squibb, Boerhinger Ingelheim, Celgene, Celltrion, Cosmo, Covidien, Ferring, DrFalk Pharma, Engene, Galapagos, Gilead, Glaxo Smith Kline, Hospira, Immunic, Johnson and Johnson, Lycera, Medimetrics, Millenium\/Takeda, Mitsubishi Pharma, Merck Sharp Dome, Mundipharma, Novonordisk, Pfizer, Prometheus laboratories\/Nestle, Protagonist, Receptos, Robarts Clinical Trials, Salix, Sandoz, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant and Vifor and received speaker fees from Abbvie, Ferring, Johnson and Johnson, Merck Sharp & Dohme, Mundipharma, Norgine, Pfizer, Shire, Millenium\/Takeda, Tillotts and Vifor.; ML: served as speaker and\/or principal investigator for Abbvie, Celgene, Covidien, Dr. Falk, Ferring Pharmaceuticals, Gilead, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Protagonist therapeutics, Receptos, Takeda, Tillotts, Tramedico and has received research grants from AbbVie, Merck Sharp & Dohme, Achmea healthcare and ZonMW.; AB: none.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this study a waiver was granted by the Medical Ethics Review Committee of the Academic Medical Center. The Medical Research Involving Human Subjects Act (WMO) did not apply to this study (W17_190).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}